Leukemia
Leukemia treated by MDM2 antagonists alone or in combination with chemotherapeutic drugs
Published in Blood Weekly, August 3rd, 2006
"B-CLL is characterized by the accumulation of long-lived CD5+ B lymphocytes. Several drugs currently used in the therapy of B-CLL act, at least partially, through activation of the p53 pathway," researchers in Spain reported.
"Recently, nongenotoxic small-molecule activators of p53, the nutlins, have been developed that inhibit p53-MDM2 binding," explained L. Collmulet and colleagues, University of Barcelona. "We have investigated the antitumor potential of nutlin-3 in B-CLL and find that it can activate the p53...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-08-03)
More Articles from Blood Weekly
- Blood Banking
Platelet discard rates are high in European blood centers - Blood Safety
Safe Blood Foundation, Chinese Ministry of Health partner to develop blood quality manual - Placental Blood Collection
Maternal placental blood collection puncture method is the best for immunology studies - Prion Transmission
Prion diagnostic and removal strategies may help control spread via blood transfusion - Acute Lymphoblastic Leukemia
GSK files for European marketing approval for Atriance as treatment for rare leukemia and lymphoma - Allergy & Immunology
Microtubule formation is regulated in activated mast cells by gamma-tubulin - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
